IRADIMED Corporation (NASDAQ: IRMD) — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. IRADIMED develops, manufactures, and sells MRI-compatible medical devices, accessories, disposables, and related services, primarily to hospitals and acute care facilities.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $16.5 million | $13.4 million | $48.1 million | $38.4 million |
| Gross profit / margin | $12.8 million / 77.8% | $10.5 million / 78.6% | $36.7 million / 76.4% | $30.1 million / 78.2% |
| Operating income | $5.9 million | $4.1 million | $14.9 million | $11.4 million |
| Net income | $5.1 million | $3.4 million | $12.7 million | $9.2 million |
| Diluted EPS | $0.40 | $0.27 | $0.99 | $0.72 |
- Q3 revenue rose 23.1%; nine-month revenue rose 25.2%. Management attributed growth to demand for patient vital signs monitors and disposables, pricing adjustments, and the release of the Ferro Magnetic Detection System.
- U.S. sales were $13.9 million in Q3, up 29.0%; international sales were $2.6 million, essentially unchanged. For the nine-month period, U.S. sales rose 23.0% to $38.9 million and international sales rose 35.1% to $9.2 million.
- Q3 device revenue increased 24.7% to $11.8 million; disposables, services, and other revenue rose 23.6% to $4.2 million. Nine-month device revenue rose 24.2% to $33.2 million, while disposables, services, and other rose 32.5% to $13.5 million.
- Gross margin declined 0.8 percentage points in Q3 and 1.8 points for the nine months. The company cited raw-material costs, overhead variances, and geographic and product mix.
- Q3 operating expenses increased to $6.9 million from $6.4 million, with higher general and administrative costs partly offset by lower sales and marketing and R&D costs. Nine-month G&A rose 35.6%, primarily due to regulatory, payroll and benefits, and legal and professional expenses.
Cash, liquidity, and balance sheet
- At September 30, 2023, cash and cash equivalents were $46.7 million, down from $58.0 million at December 31, 2022; working capital was $64.0 million and stockholders’ equity was $74.6 million.
- Nine-month operating cash flow was $9.6 million, compared with $7.0 million in 2022. Investing cash outflow was $7.4 million, including a $6.2 million land purchase; financing cash outflow was $13.4 million, primarily reflecting $13.2 million of dividends paid.
- Inventory increased to $11.7 million from $5.4 million at year-end. Management cited inventory purchases as a use of operating cash.
- No interest-bearing borrowings are reported in the supplied balance sheet; liabilities principally include deferred revenue and operating lease obligations. Total liabilities were $12.8 million.
- Management believes cash and expected operating cash generation will be sufficient for at least the next 12 months. It plans to use available cash for improvements to the land acquired for future manufacturing, research labs, and office space.
Outlook, risks, and notable items
- Management expects higher revenue for the remainder of 2023 versus the comparable 2022 period, alongside higher operating expenses, particularly sales and marketing, regulatory, and G&A costs. The filing provides no specific numerical guidance.
- Key risks include reliance on a limited number of products, FDA and other regulatory approvals or actions, sole-sourced critical components, product liability or recalls, supply interruptions, and competition. The company also identifies exposure to yen exchange-rate fluctuations, which it assessed as immaterial for the periods presented.
- The $6.2 million land purchase supports planned capacity expansion. Purchase orders for goods and services totaled $13.1 million at quarter-end; related amounts recognized on the balance sheet were described as immaterial.
- The company accrued approximately $250,000 for various legal matters, versus none at December 31, 2022; management stated that known matters are not expected to materially affect results or financial position.
- The current manufacturing and headquarters facility is leased from an entity controlled by CEO and Chairman Roger Susi. The company also reported two new office-space leases in 2023.
- Disclosure controls and procedures were judged effective as of September 30, 2023; no material changes in internal control over financial reporting were reported.
Investor facts to verify
- Whether sales growth—particularly patient-monitor sales and international revenue—continues, and whether gross-margin pressure from costs and mix eases.
- Timing, total cost, and funding of planned land development and facility expansion, alongside inventory levels and operating cash conversion.
- Regulatory developments, the availability of sole-sourced components, and any changes in legal, product-liability, or other contingencies.
- Dividend policy and the effect of future distributions on cash available for investment and operations.